Parametric Portfolio Associates’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-42,209
| Closed | -$796K | – | 4055 |
|
|
2019
Q3 | $796K | Sell |
42,209
-19,806
| -32% | -$227K | ﹤0.01% | 3143 |
|
|
2019
Q2 | $730K | Buy |
62,015
+456
| +0.7% | +$5.52K | ﹤0.01% | 3200 |
|
|
2019
Q1 | $840K | Buy |
61,559
+1,842
| +3% | +$23.9K | ﹤0.01% | 3107 |
|
|
2018
Q4 | $612K | Sell |
59,717
-2,622
| -4% | -$33.6K | ﹤0.01% | 3222 |
|
|
2018
Q3 | $1.04M | Sell |
62,339
-2,476
| -4% | -$44.8K | ﹤0.01% | 3069 |
|
|
2018
Q2 | $1.02M | Buy |
64,815
+3,793
| +6% | +$57.6K | ﹤0.01% | 3048 |
|
|
2018
Q1 | $775K | Sell |
61,022
-8,782
| -13% | -$127K | ﹤0.01% | 3138 |
|
|
2017
Q4 | $799K | Buy |
69,804
+35,610
| +104% | +$397K | ﹤0.01% | 3125 |
|
|
2017
Q3 | $419K | Sell |
34,194
-10,866
| -24% | -$113K | ﹤0.01% | 3519 |
|
|
2017
Q2 | $516K | Buy |
45,060
+25,425
| +129% | +$470K | ﹤0.01% | 3354 |
|
|
2017
Q1 | $408K | Sell |
19,635
-7,747
| -28% | -$172K | ﹤0.01% | 3299 |
|
|
2016
Q4 | $570K | Sell |
27,382
-38,987
| -59% | -$1.01M | ﹤0.01% | 3128 |
|
|
2016
Q3 | $2.17M | Sell |
66,369
-1,135
| -2% | -$34.6K | ﹤0.01% | 2280 |
|
|
2016
Q2 | $1.69M | Buy |
67,504
+26,767
| +66% | +$724K | ﹤0.01% | 2446 |
|
|
2016
Q1 | $998K | Buy |
40,737
+27,072
| +198% | +$627K | ﹤0.01% | 2933 |
|
|
2015
Q4 | $451K | Buy |
+13,665
| New | +$462K | ﹤0.01% | 3322 |
|
Parametric Portfolio Associates's ALDR Position: Q4 2019 in Review
Parametric Portfolio Associates sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 42,209 shares — an estimated $796K sold.
Parametric Portfolio Associates first reported a position in ALDR in Q4 2015 and held it in 16 quarters. The position peaked at $2.17M in Q3 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Parametric Portfolio Associates reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Parametric Portfolio Associates sold 42,209 Alder Biopharmaceuticals shares in Q4 2019, an estimated $796K.
- Parametric Portfolio Associates first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 16 quarters.
- Parametric Portfolio Associates's Alder Biopharmaceuticals position peaked at $2.17M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Parametric Portfolio Associates's 13F filing for Q4 2019, filed 14 Feb 2020.